{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:54:53Z","timestamp":1759773293837},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We aimed to determine how emerging evidence over the past decade informed how Ugandan HIV clinicians prescribed protease inhibitors (PIs) in HIV patients on rifampicin-based tuberculosis (TB) treatment and how this affected HIV treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed clinical records of HIV patients aged 13\u00a0years and above, treated with rifampicin-based TB treatment while on PIs between1st\u2014January -2013 and 30th\u2014September\u20142018 from twelve public HIV clinics in Uganda. Appropriate PI prescription during rifampicin-based TB treatment was defined as; prescribing doubled dose lopinavir\/ritonavir- (LPV\/r 800\/200\u00a0mg twice daily) and inappropriate PI prescription as prescribing standard dose LPV\/r or atazanavir\/ritonavir (ATV\/r).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 602 patients who were on both PIs and rifampicin, 103 patients (17.1% (95% CI: 14.3\u201320.34)) received an appropriate PI prescription. There were no significant differences in the two-year mortality (4.8 vs. 5.7%,<jats:italic>P<\/jats:italic>\u2009=\u20090.318), loss to follow up (23.8 vs. 18.9%,<jats:italic>P<\/jats:italic>\u2009=\u20090.318) and one-year post TB treatment virologic failure rates (31.6 vs. 30.7%,<jats:italic>P<\/jats:italic>\u2009=\u20090.471) between patients that had an appropriate PI prescription and those that did not. However, more patients on double dose LPV\/r had missed anti-retroviral therapy (ART) days (35.9 vs 21%,<jats:italic>P<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conclude that despite availability of clinical evidence, double dosing LPV\/r in patients receiving rifampicin-based TB treatment is low in Uganda\u2019s public HIV clinics but this does not seem to affect patient survival and viral suppression.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-021-06533-6","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T14:04:08Z","timestamp":1629122648000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda"],"prefix":"10.1186","volume":"21","author":[{"given":"Frank","family":"Mulindwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Kirenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Kalibbala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Haguma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Muddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred C.","family":"Semitala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"6533_CR1","unstructured":"WHO | TB causes 1 in 3 HIV deaths. WHO [Internet]. 2018 [cited 2021 Jan 4]; http:\/\/www.who.int\/hiv\/mediacentre\/news\/hiv-tb-patient-centred-care\/en\/. Accessed 4 Jan 2021."},{"issue":"7","key":"6533_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/00002030-200404300-00004","volume":"18","author":"SS Abdool-Karim","year":"2004","unstructured":"Abdool-Karim SS, Abdool-Karim Q, Friedland G, Lalloo U, El-Sadr WM. START project. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS. 2004;18(7):975\u20139.","journal-title":"AIDS"},{"key":"6533_CR3","volume-title":"WHO, Policy on collaborative TB\/HIV activities","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. WHO, Policy on collaborative TB\/HIV activities. Geneva: World Health Organization; 2012."},{"key":"6533_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2013.02.003","author":"KL Dierberg","year":"2013","unstructured":"Dierberg KL, Chaisson RE. Human immunodeficiency virus-associated tuberculosis. Update on prevention and treatment. Clin Chest Med. 2013. https:\/\/doi.org\/10.1016\/j.ccm.2013.02.003.","journal-title":"Clin Chest Med"},{"key":"6533_CR5","volume-title":"Guidelines on tuberculosis infection prevention and control","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Guidelines on tuberculosis infection prevention and control. Geneva: World Health Organization; 2019."},{"issue":"1","key":"6533_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","volume":"18","author":"SE Dorman","year":"2018","unstructured":"Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB\/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76\u201384.","journal-title":"Lancet Infect Dis"},{"key":"6533_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/arh.2017.08.08","volume":"1","author":"K Kumar","year":"2017","unstructured":"Kumar K, Kon OM. Diagnosis and treatment of tuberculosis: latest developments and future priorities. Ann Res Hosp. 2017;1:1\u20131.","journal-title":"Ann Res Hosp"},{"issue":"6","key":"6533_CR8","doi-asserted-by":"publisher","first-page":"e0198695","DOI":"10.1371\/journal.pone.0198695","volume":"13","author":"T Metcalf","year":"2018","unstructured":"Metcalf T, Soria J, Montano SM, Ticona E, Evans CA, Huaroto L, et al. Evaluation of the GeneXpert MTB\/RIF in patients with presumptive tuberculous meningitis. PLoS ONE. 2018;13(6):e0198695.","journal-title":"PLoS ONE"},{"key":"6533_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01717-18","author":"O Opota","year":"2019","unstructured":"Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added value of Xpert MTB\/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. J Clin Microbiol. 2019. https:\/\/doi.org\/10.1128\/JCM.01717-18.","journal-title":"J Clin Microbiol"},{"key":"6533_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169798","author":"P Pandey","year":"2017","unstructured":"Pandey P, Pant ND, Rijal KR, Shrestha B, Kattel S, Banjara MR, et al. Diagnostic Accuracy of GeneXpert MTB\/RIF assay in comparison to conventional drug susceptibility testing method for the diagnosis of multidrug-resistant tuberculosis. PLoS ONE. 2017. https:\/\/doi.org\/10.1371\/journal.pone.0169798.","journal-title":"PLoS ONE"},{"key":"6533_CR11","doi-asserted-by":"crossref","unstructured":"Shah W. To determine diagnostic accuracy of gene xpert and sputum Ziehl-Neelsen staining taking sputum culture as gold standard. In: European Respiratory Society (ERS); 2016. p. PA2779.","DOI":"10.1183\/13993003.congress-2016.PA2779"},{"key":"6533_CR12","unstructured":"WHO | Next-generation Xpert\u00ae MTB\/RIF Ultra assay recommended by WHO. WHO [Internet]. 2017. http:\/\/www.who.int\/tb\/features_archive\/Xpert-Ultra\/en\/. Accessed 7 Oct 2020."},{"issue":"16","key":"6533_CR13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"F-X Blanc","year":"2011","unstructured":"Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1013911.","journal-title":"N Engl J Med"},{"issue":"16","key":"6533_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","volume":"365","author":"DV Havlir","year":"2011","unstructured":"Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1013607.","journal-title":"N Engl J Med"},{"issue":"10","key":"6533_CR15","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1128\/AAC.00461-06","volume":"50","author":"DM Burger","year":"2006","unstructured":"Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3336\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"6533_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1086\/380794","volume":"38","author":"US Justesen","year":"2004","unstructured":"Justesen US, Andersen \u00c5B, Klitgaard NA, Br\u00f8sen K, Gerstoft J, Pedersen C. pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis. 2004;38(3):426\u20139.","journal-title":"Clin Infect Dis"},{"key":"6533_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044793","author":"RA Murphy","year":"2012","unstructured":"Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of Lopinavir\/Ritonavir and Rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0044793.","journal-title":"PLoS ONE"},{"key":"6533_CR18","unstructured":"CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2014."},{"key":"6533_CR19","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000358","author":"CA Stanis Schmaltz","year":"2014","unstructured":"Stanis Schmaltz CA, Martins Costa MJ, Cattani VB, Pereira Pinto D, Liporage J, Benjamin A, et al. Pharmacological interaction of Lopinavir\/Ritonavir 800\/200 mg BID and rifampicin in subjects presenting tuberculosis with contraindication for an efavirenz containing antiretroviral regimen. J AIDS Clin Res. 2014. https:\/\/doi.org\/10.4172\/2155-6113.1000358.","journal-title":"J AIDS Clin Res."},{"issue":"12","key":"6533_CR20","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/cid\/cit654","volume":"57","author":"T Vijayan","year":"2013","unstructured":"Vijayan T, Semitala FC, Matsiko N, Elyanu P, Namusobya J, Havlir DV, et al. Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV\/AIDS. Clin Infect Dis. 2013;57(12):1766\u201372.","journal-title":"Clin Infect Dis"},{"key":"6533_CR21","volume-title":"TB-HIV fact sheet","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. TB-HIV fact sheet. Geneva: World Health Organization; 2018."},{"issue":"7","key":"6533_CR22","doi-asserted-by":"publisher","first-page":"e1001067","DOI":"10.1371\/journal.pmed.1001067","volume":"8","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB\/RIF assay: a prospective study. PLoS Med. 2011;8(7):e1001067.","journal-title":"PLoS Med"},{"key":"6533_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijid.2017.01.023","volume":"56","author":"TJ Nagu","year":"2017","unstructured":"Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, et al. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Inf Dis. 2017;56:39\u201344.","journal-title":"Int J Inf Dis"},{"issue":"6","key":"6533_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/COH.0000000000000502","volume":"13","author":"NF Walker","year":"2018","unstructured":"Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS. 2018;13(6):512\u201321.","journal-title":"Curr Opin HIV AIDS"},{"key":"6533_CR25","unstructured":"High TB Risk in HIV-Positive Patients on Second-Line Antiretrovirals in Pune, India - CROI Conference [Internet]. https:\/\/www.croiconference.org\/abstract\/high-tb-risk-hiv-positive-patients-second-line-antiretrovirals-pune-india\/. Accessed 7 Oct 2020."},{"key":"6533_CR26","unstructured":"Health MOF. Ministry of health consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. 2020; (February)."},{"issue":"5","key":"6533_CR27","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","volume":"48","author":"CJL la Porte","year":"2004","unstructured":"la Porte CJL, Colbers EPH, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(5):1553\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"6533_CR28","unstructured":"Geneva. 7th Expert Committee on the Selection and Use of Essential Medicines WHO model list of essential medicines application. 2009."},{"key":"6533_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25333","author":"N Rockwood","year":"2019","unstructured":"Rockwood N, Cerrone M, Barber M, Hill AM, Pozniak AL. Global access of rifabutin for the treatment of tuberculosis\u2014why should we prioritize this? J Int AIDS Soc. 2019. https:\/\/doi.org\/10.1002\/jia2.25333.","journal-title":"J Int AIDS Soc"},{"key":"6533_CR30","unstructured":"Of Rwanda R, of Health M. Republic of Rwanda Ministry of Health National Guidelines for Prevention and Management of HIV and STIs. 2016."},{"key":"6533_CR31","unstructured":"African S. National for the management of HIV in adults, adolescents, children and infants and prevention of mother-to-child transmission. 2020."},{"key":"6533_CR32","unstructured":"National Guidelines on the Use of Antiretroviral Therapy for HIV Prevention and Treatment Fifth Edition Government of Lesotho Ministry of Health National Guidelines for HIV & AIDS Care and Treatment (5th Edition) National Guidelines for HIV & AIDS Care and Treatment (4th Edition). 2016."},{"key":"6533_CR33","unstructured":"I National Guidelines for Antiretroviral Therapy-Sixth Edition."},{"issue":"8","key":"6533_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3851\/IMP1455","volume":"14","author":"G Maartens","year":"2009","unstructured":"Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14(8):1039\u201343.","journal-title":"Antivir Ther"},{"key":"6533_CR35","unstructured":"Rana F, et al. Rifampicin-an overview. IJRPC 2013;3(1):83\u201387."},{"issue":"3","key":"6533_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","volume":"50","author":"DW Haas","year":"2009","unstructured":"Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50(3):290\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"6533_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1753-5174.2009.00017.x","volume":"2","author":"C Schmitt","year":"2009","unstructured":"Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of rifampin and saquinavir\/ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2(1):8\u201316.","journal-title":"Arch Drug Inf"},{"key":"6533_CR38","volume-title":"Consolidated guidelines on the use of ARVs","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Consolidated guidelines on the use of ARVs. Geneva: World Health Organization; 2016."},{"key":"6533_CR39","unstructured":"MoH Uganda. Uganda HIV treatment guidelines. 2016."},{"key":"6533_CR40","unstructured":"MoH Uganda. Uganda HIV treatment guidelines."},{"key":"6533_CR41","unstructured":"MoH Uganda. Uganda HIV treatment guidelines. 2018."},{"key":"6533_CR42","unstructured":"Uganda HIV\/AIDS Country Progress Report July 2017-June 2018. 2017."},{"key":"6533_CR43","unstructured":"UNAIDS. 0-90-90: An ambitious treatment target to help end the AIDS epidemic. 2014."},{"key":"6533_CR44","unstructured":"Manual for Management and Control of Tuberculosis and Leprosy 3rd edition March 2017\u2014Ministry of Health | Government of Uganda [Internet]. https:\/\/www.health.go.ug\/cause\/manual-for-management-and-control-of-tuberculosis-and-leprosy-3rd-edition-march-2017\/. Accessed 7 Oct 2020."},{"key":"6533_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-9-192","author":"JB Babigumira","year":"2009","unstructured":"Babigumira JB, Castelnuovo B, Lamorde M, Kambugu A, Stergachis A, Easterbrook P, et al. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res. 2009. https:\/\/doi.org\/10.1186\/1472-6963-9-192.","journal-title":"BMC Health Serv Res"},{"key":"6533_CR46","volume-title":"WHO, Task shifting to tackle heatlh worker shortages","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. WHO, Task shifting to tackle heatlh worker shortages. Geneva: World Health Organization; 2007."},{"issue":"5","key":"6533_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jinf.2019.03.003","volume":"78","author":"FS Sarfo","year":"2019","unstructured":"Sarfo FS, Castelnuovo B, Fanti I, Feldt T, Incardona F, Kaiser R, et al. Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics. J Infect. 2019;78(5):402\u20138.","journal-title":"J Infect"},{"key":"6533_CR48","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.21327","author":"L Fenner","year":"2017","unstructured":"Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Z\u00fcrcher K, et al. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. J Int AIDS Soc. 2017. https:\/\/doi.org\/10.7448\/IAS.20.1.21327.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"6533_CR49","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.bulm.2005.01.006","volume":"67","author":"L Jones","year":"2005","unstructured":"Jones L, Perelson A. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol. 2005;67(6):1227\u201351. https:\/\/doi.org\/10.1016\/j.bulm.2005.01.006.","journal-title":"Bull Math Biol"},{"issue":"4","key":"6533_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ebiom.2015.03.005","volume":"2","author":"ZA Sullivan","year":"2015","unstructured":"Sullivan ZA, Wong EB, Ndung\u2019u T, Kasprowicz VO, Bishai WR. Latent and active tuberculosis infection increase immune activation in individuals co-infected with HIV. EBioMedicine. 2015;2(4):334\u201340.","journal-title":"EBioMedicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06533-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T12:46:34Z","timestamp":1673095594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6533"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06533-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Makerere University School of Medicine Research and Ethics Committee (approval number: 208\u2013112) and the Uganda National Council of Science and Technology (approval number; HS2576). The requirement for informed consent to review the HIV clinic medical records was waivered by the Makerere University School of Medicine Research and Ethics Committee. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}